Clinical Trials · NCT03767543
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 265
- Start date
- Mar 2019
- Locations
- 32 sites, Canada
- Primary endpoint
- Change in glycated hemoglobin (HbA1c)%